Perrigo Company plc
PRGOBusiness Overview
source: coverage-next-full ticker: PRGO step: "01" title: Business Overview — Perrigo Company plc created: 2026-05-29
Step 01 — Business Overview
Company at a Glance
Perrigo Company plc is the world's largest manufacturer of over-the-counter (OTC) store-brand (private-label) consumer healthcare products. Headquartered in Dublin, Ireland, and listed on the NYSE, Perrigo operates as the hidden engine behind the store-brand OTC medicine shelves at Walmart, CVS, Walgreens, Target, Costco, Kroger, and Amazon. When a consumer reaches for the CVS-brand ibuprofen instead of Advil, there is a high probability it was manufactured by Perrigo.
The company pivoted decisively in 2021 by divesting its Rx pharmaceutical generics business to become a pure-play consumer self-care company. The subsequent acquisition of HRA Pharma in 2022 added a branded international OTC portfolio — shifting the mix toward branded products in Europe while maintaining the dominant private-label position in the Americas.
What Perrigo Does
Perrigo's core value proposition is straightforward: it develops, manufactures, and distributes store-brand equivalents of branded OTC products at materially lower prices, giving retailers high-margin, lower-cost alternatives to national brands. This "value brand" model benefits retailers (higher private-label margins vs. branded resale) and consumers (20–30% savings on therapeutically equivalent products).
Secondary value: In international markets (primarily Europe), Perrigo owns branded OTC products — not private-label — that compete directly with Haleon, Kenvue, and Reckitt product lines.
Business Segments
Consumer Self-Care Americas (CSCA) — ~55–67% of Revenue
The flagship segment. CSCA is the largest private-label OTC manufacturer in the United States. It manufactures and distributes store-brand equivalents across categories:
| Category | Example Products | National Brand Equiv. |
|---|---|---|
| Analgesics | Store-brand ibuprofen, acetaminophen | Advil, Tylenol |
| Cough / Cold / Allergy | Store-brand DXM, guaifenesin, loratadine | NyQuil, Mucinex, Claritin |
| Gastrointestinal | Store-brand antacids, laxatives, anti-diarrheal | Tums, Dulcolax, Imodium |
| Smoking Cessation | Store-brand nicotine patches, gum | Nicorette, NicoDerm |
| Infant Nutrition | Store-brand infant formula | Similac, Enfamil (Abbott, Reckitt) |
| Women's Health | Opill® (OTC oral contraceptive) | First-mover in new OTC category |
| Eye / Ear Care | Store-brand eye drops, ear wax kits | Visine, Debrox |
Opill® (norgestrel 0.075mg) is noteworthy: the first-ever FDA-approved daily oral contraceptive available OTC without a prescription. Approved July 2023, launched early 2024. Perrigo holds the exclusive OTC right, representing a rare branded growth vector within CSCA.
Infant Formula (~$360M revenue, ~8–9% of total): Perrigo is the largest US private-label infant formula manufacturer (a market segment not supplied by Abbott or Mead Johnson). The 2022 Abbott recall created a temporary windfall. A strategic review was announced in November 2025 to evaluate divestiture or other options.
Consumer Self-Care International (CSCI) — ~33–45% of Revenue
A branded OTC portfolio in Europe and Australia, significantly enlarged by the HRA Pharma acquisition. Key brands:
| Brand | Category | Primary Markets |
|---|---|---|
| Compeed® | Blister/wound care | Europe-wide |
| Solpadeine® | Analgesic (codeine-containing) | UK, Ireland |
| Coldrex® | Cold/flu remedy | Central/Eastern Europe |
| Mederma® | Scar treatment | Europe |
| ellaOne® | Emergency contraceptive (HRA) | Europe |
| Plan B® | Emergency contraceptive (HRA, US) | US/Americas |
| Dermacosmetics | Skincare | Europe (under divestiture review) |
HRA Pharma also brought a pipeline of Rx-to-OTC switch projects — a strategic growth avenue for branded consumer health across Europe.
Transformation Story (2021–2026)
Perrigo's recent history is defined by two decisions of opposing nature:
Rx Divestiture (2021): Sold the prescription generics business, refocusing on consumer OTC. This simplified the business and reduced generic pharma pricing/volume risk. It also generated cash, temporarily improving the balance sheet.
HRA Pharma Acquisition (2022): Paid ~€1.8B for HRA Pharma, funded predominantly with debt. This added branded European OTC and reproductive health products (ellaOne, Plan B) but substantially levered the balance sheet (net leverage jumped to ~5x). Post-acquisition integration has been the dominant strategic focus since.
The net result: Perrigo is now a mid-complexity consumer health company with a leading private-label US franchise, a branded European portfolio, and a leveraged balance sheet in need of repair.
Key Facts
| Metric | Value (May 2026) |
|---|---|
| Market Cap | ~$1.58B |
| Annual Revenue | ~$4.25B (FY2025) |
| Employees | ~9,000–10,000 |
| Listed | NYSE (PRGO); Euronext Dublin |
| Incorporated | Ireland |
| Fiscal Year | Calendar year (Dec 31) |
| Dividend | $1.16/share (~10% yield) |
| Net Leverage | ~4.5x adj. EBITDA (FY2025 est.) |
Financial Snapshot
source: coverage-next-full ticker: PRGO step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29
Step 04 — Financial Snapshot
Annual P&L Summary (USD millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Commentary |
|---|---|---|---|---|---|
| Revenue | $4,452 | $4,656 | $4,373 | $4,253 | Declining since FY2023 peak |
| Gross Profit | $1,455 | $1,680 | $1,543 | $1,495 | — |
| Gross Margin % | 32.7% | 36.1% | 35.3% | 35.2% | Recovered from HRA-dilution low |
| Operating Income (GAAP) | $79 | $152 | $113 | -$1,122 | FY2025 devastated by impairments |
| EBIT Margin (GAAP) | 1.8% | 3.3% | 2.6% | -26.4% | Not meaningful; impairment-driven |
| Adj. EBITDA | ~$418 | ~$511 | ~$439 | n/m | Adjusted basis used by company |
| Adj. EBITDA Margin | ~9.4% | ~11.0% | ~10.0% | est. ~10–11% | Approximately stable core profitability |
| Net Income (GAAP) | -$141 | -$13 | -$172 | -$1,425 | Perennial GAAP losses; impairments + interest |
| EPS Diluted (GAAP) | -$1.04 | -$0.09 | -$1.25 | -$10.29 | FY2025 massive impairment |
| Adj. EPS (Non-GAAP) | n/a | n/a | est. ~$2.60 | est. ~$2.50 | Management's preferred earnings metric |
Key Note on GAAP vs. Adjusted: Perrigo's GAAP financials are persistently negative due to (1) non-cash amortization of acquired intangibles from HRA Pharma and other M&A, and (2) recurring restructuring/impairment charges. The FY2025 GAAP net loss of -$1,425M was driven primarily by ~$1.3B+ in non-cash goodwill and intangible impairments (Q4 2025 and Q1 2026 charges) tied to the CSCI portfolio revaluation following the Dermacosmetics divestiture announcement and weaker-than-expected performance. Management and analysts focus on adjusted EPS (excluding amortization, impairments, restructuring) for normalized earnings power. Adjusted EPS of ~$2.50 in FY2025 vs. GAAP EPS of -$10.29 illustrates the magnitude of these adjustments.
Revenue Trend Analysis
Revenue grew from $4,139M in FY2021 to a peak of $4,656M in FY2023 (+12.5% over 2 years), benefiting from:
- HRA Pharma consolidation (added ~$500–600M of CSCI revenue from mid-2022)
- Abbott infant formula recall market share gains (2022)
- Post-COVID cough/cold volume recovery
The subsequent decline to $4,373M (FY2024) and $4,253M (FY2025) reflects:
- CSCA softness: competitive pricing pressure and infant formula volume normalization
- CSCI headwinds: unfavorable currency, Dermacosmetics under review
- Absence of 2022's non-repeating infant formula windfall
FY2026 consensus: ~$4,140M (-2.7% further decline), as divestitures partially offset Opill ramp and Project Energize cost savings.
Gross Margin Analysis
Gross margin collapsed to 32.7% in FY2022 (HRA integration costs, supply chain inflation, working capital build) then recovered to 36.1% in FY2023. FY2024–FY2025 stabilization at ~35% represents the new normalized level. Management targets 22–24% adjusted EBIT margin (implying incremental operating leverage above the current ~35% gross margin level). Adjusted EBIT margin in FY2024 was roughly 10–11%, leaving a gap vs. target.
Cost Structure
| Cost Line | Est. % of Revenue | Commentary |
|---|---|---|
| COGS | ~65% | Manufacturing, raw materials, packaging |
| SG&A | ~15–18% | Marketing (CSCI branded), corporate overhead |
| R&D | ~3–5% | Primarily Rx-to-OTC switch development (HRA heritage) |
| Amortization | ~6–8% | HRA intangibles ($3.2B acquired intangible base) |
| Restructuring | ~1–2% | Project Energize ongoing |
The dominant intangible amortization burden (~$250–350M/year) is the primary driver of the GAAP vs. adjusted divergence.
Interest Expense
With ~$3.6B in total debt, interest expense is substantial:
- FY2024: ~$210–230M (estimated at ~5.5–6% blended rate on mix of fixed senior notes and floating revolver)
- FY2025: similar level — ~$200–225M
Interest expense effectively absorbs approximately half of adjusted EBITDA (~$450M), leaving FCF generation thin relative to debt level.
Adjusted EBITDA Trend
| Year | Adj. EBITDA | Adj. EBITDA Margin | Commentary |
|---|---|---|---|
| FY2022 | ~$418M | ~9.4% | HRA integration drag |
| FY2023 | ~$511M | ~11.0% | Best recent performance |
| FY2024 | ~$439M | ~10.0% | Revenue decline + pricing pressure |
| FY2025 | ~$400–440M (est.) | ~9.5–10.3% | Project Energize saves begin; volume headwinds |
| FY2026E | ~$450–480M (est.) | ~10.9–11.6% | Energize savings ramp + divestitures |
Management is targeting a path to 22–24% adjusted EBIT margin, roughly double the FY2024–FY2025 level, through Project Energize ($140–170M gross savings by end-2026) and portfolio optimization.
EPS Bridge (GAAP to Adjusted)
Starting from GAAP EPS of -$1.25 (FY2024):
- Add back: ~$250–300M amortization of acquisition-related intangibles
- Add back: ~$50–100M restructuring/impairment charges
- Add back: ~$30–50M non-cash share-based comp and other items
- Tax impact on adjustments
- Approximate adjusted EPS ≈ $2.50–2.70
This bridge is essential for evaluating whether the business is generating real economic returns. The ~$280M+ in annual amortization from HRA is a non-cash charge that distorts GAAP earnings for 10–15 years post-acquisition.
Three-Year P&L Scorecard
| KPI | FY2022 | FY2023 | FY2024 | Trend |
|---|---|---|---|---|
| Revenue Growth | +7.6% | +4.6% | -6.1% | Declining |
| Gross Margin | 32.7% | 36.1% | 35.3% | Recovering/Stable |
| Adj. EBITDA Margin | ~9.4% | ~11.0% | ~10.0% | Volatile |
| FCF ($M) | $211 | $304 | $245 | Declining |
| GAAP Net Loss ($M) | -$141 | -$13 | -$172 | Persistently negative |
| Net Debt ($B) | ~$3.5 | ~$3.3 | ~$3.1 | Gradually declining |
| Dividend Covered by FCF? | Yes | Yes | Yes (barely) | Thin coverage |
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $PRGO.